TJ Chao, PA-C: Considering Adverse Events in Patients with Atopic Dermatitis
TJ Chao breaks down the black box warnings for ruxolitinib cream 1.5% and discusses the importance in communicating the specifics of these warnings to patients.
Raj Chovatiya, MD: Key Ingredients in Moisturizers for Atopic Dermatitis
Dr. Chovatiya reviews some of the essentials to look for in moisturizers such as a treatment that is semipermeable and has natural moisturizing factors.
Dr. Chovatiya discusses the benefits of a moisturization routine as a complement to all currently available therapies for patients with atopic dermatitis.
TJ Chao, PA-C: Utilizing Topical Treatments for Patients with Atopic Dermatitis
Mr. Chao discusses the reliability of ruxolitinib cream 1.5% in treating patients with atopic dermatitis. He emphasized how well it is tolerated by patients, as
Matthew Zirwas, MD: Revolution of Topical Treatments in Atopic Dermatitis
Dr. Matthew Zirwas reviews atopic dermatitis treatments that have been essential in providing immediate improvement in itch leading to a sense of control in his
Jonathan I. Silverberg, MD, PhD, MPH, FAAD: Patient Counseling in Atopic Dermatitis
Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.
Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
Raj Chovatiya, MD, PhD: Explaining the Mechanisms and Advantages of JAK Inhibitors
Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
Seemal Desai, MD, FAAD: The Newest JAK Inhibitors for Inflammatory Skin Diseases
Seemai Desai, MD, FAAD, a dermatologist in private and academic practice in Dallas, Texas, discusses the development and use of JAK inhibitors for inflammatory skin
Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr.
